PAR2 signaling activates histamine-independent itching pathways, like the release of pruritogenic mediators and increased expression of TSLP, and histamine antagonists are known to be less effective as treatment for atopic dermatitis-related itch. Here, F2RL1 is linked to atopic eczema.